140 related articles for article (PubMed ID: 28737025)
21. Effects of systemic steroids on patients with community-acquired pneumonia: Observational study from a tertiary care hospital of a developing country.
Iqbal N; Irfan M; Siddiqui F; Arshad V; Zuabairi ABS
Respir Investig; 2020 Nov; 58(6):495-501. PubMed ID: 32665194
[TBL] [Abstract][Full Text] [Related]
22. Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome.
Polverino E; Cillóniz C; Dambrava P; Gabarrús A; Ferrer M; Agustí C; Prina E; Montull B; Menendez R; Niederman MS; Torres A
Respirology; 2013 Feb; 18(2):263-71. PubMed ID: 23134361
[TBL] [Abstract][Full Text] [Related]
23. Variation in management of community-acquired pneumonia requiring admission to Alberta, Canada hospitals.
Jin Y; Marrie TJ; Carriere KC; Predy G; Houston C; Ness K; Johnson DH
Epidemiol Infect; 2003 Feb; 130(1):41-51. PubMed ID: 12613744
[TBL] [Abstract][Full Text] [Related]
24. Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity.
Cupurdija V; Lazic Z; Petrovic M; Mojsilovic S; Cekerevac I; Rancic N; Jakovljevic M
J Bras Pneumol; 2015; 41(1):48-57. PubMed ID: 25750674
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the impact of an antimicrobial stewardship program on the length of stay of immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired pneumonia: A quasi-experimental study.
DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
Am J Infect Control; 2016 May; 44(5):e73-9. PubMed ID: 26899527
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
Kessler LA; Waterer GW; Barca R; Wunderink RG
Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia.
Justo D; Lachmi S; Saar N; Joffe E; Atzmony L; Mashav N; Henis O; Sade B; Chundadze T; Steinvil A; Paran Y
Eur J Intern Med; 2009 Sep; 20(5):518-21. PubMed ID: 19712857
[TBL] [Abstract][Full Text] [Related]
28. Improved management of community-acquired pneumonia in the emergency department.
Julián-Jiménez A; Palomo de los Reyes MJ; Parejo Miguez R; Laín-Terés N; Cuena-Boy R; Lozano-Ancín A
Arch Bronconeumol; 2013 Jun; 49(6):230-40. PubMed ID: 23477946
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia.
Paladino JA; Gudgel LD; Forrest A; Niederman MS
Chest; 2002 Oct; 122(4):1271-9. PubMed ID: 12377852
[TBL] [Abstract][Full Text] [Related]
30. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
Zhou QT; He B; Zhu H
Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
[TBL] [Abstract][Full Text] [Related]
31. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
32. Severity and outcomes of community acquired pneumonia in asthmatic patients.
Terraneo S; Polverino E; Cilloniz C; Amaro R; Vennera Mdel C; Gabarrus A; Montull B; Moreno E; Menendez R; Centanni S; Torres A
Respir Med; 2014 Nov; 108(11):1713-22. PubMed ID: 25245791
[TBL] [Abstract][Full Text] [Related]
33. Reducing door-to-antibiotic time in community-acquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis.
Barlow G; Nathwani D; Williams F; Ogston S; Winter J; Jones M; Slane P; Myers E; Sullivan F; Stevens N; Duffey R; Lowden K; Davey P
Thorax; 2007 Jan; 62(1):67-74. PubMed ID: 16928714
[TBL] [Abstract][Full Text] [Related]
34. [Effect of clinical pathway management on pediatric pneumonia].
Yang Y; Yin LJ; Peng DH; Huang Y; Dai JH
Zhonghua Er Ke Za Zhi; 2013 Oct; 51(10):793-7. PubMed ID: 24406236
[TBL] [Abstract][Full Text] [Related]
35. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study.
Basille D; Plouvier N; Trouve C; Duhaut P; Andrejak C; Jounieaux V
Lung; 2017 Apr; 195(2):201-208. PubMed ID: 28005149
[TBL] [Abstract][Full Text] [Related]
36. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
[TBL] [Abstract][Full Text] [Related]
37. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Brown PD
Pharmacoeconomics; 2004; 22(7):413-20. PubMed ID: 15137880
[TBL] [Abstract][Full Text] [Related]
38. A clinical pathway for community-acquired pneumonia: an observational cohort study.
Frei CR; Bell AM; Traugott KA; Jaso TC; Daniels KR; Mortensen EM; Restrepo MI; Oramasionwu CU; Ruiz AD; Mylchreest WR; Sikirica V; Raut MR; Fisher A; Schein JR
BMC Infect Dis; 2011 Jul; 11():188. PubMed ID: 21733161
[TBL] [Abstract][Full Text] [Related]
39. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department.
Micek ST; Lang A; Fuller BM; Hampton NB; Kollef MH
BMC Infect Dis; 2014 Feb; 14():61. PubMed ID: 24499035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
